1 / 8

Ophthalmic Drugs Market Analysis and In-depth study on market Size Trends

Global Ophthalmic Drugs Market size was valued at $29,613 million in 2016, and is expected to reach $42,663 million by 2023, registering a CAGR of 5.3% from 2017 to 2023. Ophthalmic drugs are extensively used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders.<br>Read more and Get Sample PDF of Report @ https://www.alliedmarketresearch.com/request-sample/310

shawn966
Download Presentation

Ophthalmic Drugs Market Analysis and In-depth study on market Size Trends

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. According to a new report published by Allied Market Research, titled, "Ophthalmic Drugs Market by Indication, Type, Distribution Channel, Dosage Form, Technology, and Therapeutic Class: Global Opportunity Analysis and Industry Forecast, 2017-2023", the global ophthalmic drugs market was valued at $29,613 million in 2016, and is projected to reach $42,663 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. The retinal disorders segment accounted for 26.6% of the global ophthalmic drugs market in 2016. Ophthalmic Drugs Market

  2. The development of effective ophthalmic is crucial is the current scenario, owing to increase in incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. Ophthalmic drugs are administered in different dosage forms depending upon the indication. Market players focus on innovation of novel approaches for the development of ophthalmic drugs over the years, including small molecule, biologics, and recombinant technologies, thereby driving the growth of ophthalmic drugs market. • Increase in focus towards developing combination therapies for treatment of ophthalmic disorders, prevalence of these disorders, and surge in geriatric population are projected to drive the ophthalmic drugs market growth. In addition, continuous change in demographics worldwide supplements this growth. However, longer timelines required for the approval of novel ophthalmic drugs and side effects associated with the same limit market expansion.

  3. Market By Dosage Form

  4. Key Findings of the Ophthalmic Drugs Market: • The liquid ophthalmic drug forms generated the highest revenue in 2016, and are anticipated to continue the same trend, registering a CAGR of 4.1% from 2017 to 2023. • The cell therapy technologies registered significant growth rate and is expected to register a CAGR of 6.5%. • North America dominated the market, accounting for maximum share of 36% of the total market in 2016 and is expected to witness a CAGR of 4.4%. • The online pharmacies segment is witnessing the highest CAGR of 5.8% among the end users. • Anti-inflammatory drugs accounted for two-sevenths share of the global ophthalmic drugs market in 2016.

  5. Key players: • Santen Pharmaceutical Co.Ltd.• Bausch & Lomb Inc. (Valeant Pharmaceuticals International Inc.)• Shire Plc• Alcon (Novartis)• Genentech Inc. • Allergan Plc• Sun Pharmaceutical Industries Limited• Actavis Generics (Teva Pharmaceutical Industries Ltd.)• Regeneron Pharmaceuticals Inc. • Pfizer Inc.

  6. Market By Indication

  7. Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small Molecule, and Others), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, and Others), and Therapeutic Class (Anti-glaucoma, Anti-infection, Anti-inflammatory, and Anti-allergy) - Global Opportunity Analysis and Industry Forecast, 2017-2023

More Related